# PMC Biogenix to build new Armoslip facility in Gyeongju, South Korea

PMC Biogenix announced the construction of a new Armoslip facility in Gyeongju, South Korea, increasing production capacity by 50%. Construction will begin in late 2024 with new supply available by mid-2026.

- Type: New facility
- Announced: 2024-06-23
- Where: Gyeongju, South Korea, South Korea
- Starts operating: Jul 2026
- Status: announced
- Capacity: 50% increase
- Products: Armoslip specialty fatty amides
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [PMC Biogenix](https://endata.com/companies/22493.md)
- [PMC Group](https://endata.com/companies/995.md) (partner)

## Sources

- [koreanewswire.co.kr](https://www.koreanewswire.co.kr/newsRead.php?no=992057), 2024-06-23: "We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products."
- [newswire.co.kr](https://www.newswire.co.kr/newsRead.php?no=992057), 2024-06-23: "We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.